The global liver fibrosis treatment market, valued at USD 16.43 billion in 2022, is projected to reach a remarkable USD 46.65 billion by 2033, growing at an impressive CAGR of 11% during the forecast period of 2023 to 2033, according to a comprehensive study by Future Market Insights.
Liver fibrosis, a significant symptom of various liver disorders, is increasingly becoming a focus for healthcare professionals who are dedicated to slowing down or halting the scarring of the liver. The condition, while not a standalone disease, is closely associated with a range of risk factors including autoimmune hepatitis, chronic alcoholism, and metabolic storage disorders such as Galactosemia, Wilson disease, glycogen storage diseases, Gaucher disease, Fructosemia, and iron-overload syndromes. Additionally, certain viral and parasitic infections, which adversely affect hepatic blood flow, further complicate the management of liver fibrosis.
One of the critical drivers of growth in the liver fibrosis treatment market is the surge in Non-alcoholic Steatohepatitis (NASH) cases. The market is witnessing exponential growth in NASH treatment, with several private research organizations dedicating substantial resources to the development of therapies targeting liver fibrosis and other fatty liver diseases. This trend is expected to propel the market significantly over the coming decade.
A notable milestone in the treatment of liver-related disorders was achieved in April 2019 when the U.S. Food and Drug Administration (FDA) approved Mavyret by AbbVie. This approval marked the first confirmed treatment for pediatric Hepatitis C patients across all genotypes, underscoring the importance of innovative treatments in combating liver fibrosis and related conditions.
However, the market faces challenges, particularly the high costs associated with liver fibrosis treatment. The Centers for Disease Analysis report that the United States alone spends approximately USD 5 billion annually on healthcare costs related to liver diseases, including hospitalizations, screenings, transplants, and chemotherapy. These financial burdens could potentially hinder market growth.
The National Institute of Health has identified Non-alcoholic Fatty Liver Disease (NAFLD) as the most prevalent form of liver disease globally, accounting for 25% of cases. In the U.S., a variant of NAFLD, Non-alcoholic Steatohepatitis (NASH), affects about 5% of the population, further highlighting the urgent need for effective liver fibrosis treatments.
Future Market Insights’ latest report, “Liver Fibrosis Treatment Market,” offers an in-depth analysis of these trends and forecasts a robust growth trajectory for the market. The report is backed by a team of seasoned analysts and consultants who have employed a bottom-up approach in their primary, secondary, and tertiary research methodologies.
“With growing incidences of liver disorders, the global liver fibrosis treatment market is expected to grow on an unprecedented note going forward,” says an analyst from Future Market Insights.
Key Takeaways from Liver Fibrosis Treatment Market
- North America holds the largest market share with a plethora of drug molecules available for improving treatment process with technological development in this region’s rehabilitation. Also, the key participants are into increasingly spending on healthcare. Also, the fact that NAFLD (Non-Alcoholic Fatty Liver Disorder) ends up affecting close to 20% of Canadians can’t be let off.
- The Asia-Pacific is expected to grow at the quickest rate in the liver fibrosis treatment market on the back of advancements in the medical infrastructure in countries like India, China, and the other South-East Asian economies. Also, there is a growing pool of people contracting Hepatitis C herein.
Stay Ahead with Liver Fibrosis Treatment: Delve into Our Full Report for Extensive Trends and Insights!
Competitive Treatment
- Aligos Therapeutics Inc., in December 2020, did enter into collaboration with Merck & Co. Inc. for creating a therapy regarding liver fibrosis treatment.
- Gilead Sciences Inc., in March 2019, did launch HepConnect Program for reducing Hepatitis C Infections in ‘Greater Appalachia’.
- Beijing Continent Pharmaceutical Co., Ltd., in January 2022, upgraded clinical trial regarding Hydronidone capsules to phase 3. It had finished with an effective Phase II clinical trial in December 2021. The Phase III trial is expected to be completed in June 2024.
- HepC, under its vector scheme, has its non-pathogenic double-stranded RNA virus behave as one of the expert inducers of anti-viral gene reactions. It is into development of HC001 for curing chronic viral hepatitis caused due to HCV and HBV infections.
What does the Report say?
- The research study is based on treatment type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE inhibitors, hepatotropic drug, and likewise), condition (chronic liver diseases, Hepatitis C, and non-alcoholic steatohepatitis), and end-user (hospitals, specialty clinics, and likewise).
- With fatalities out of cirrhosis of liver on the rise, the global liver fibrosis treatment market is bound to grow on an astonishing note going forward.
Key Companies Profiled:
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Johnson and Johnson
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- FibroGen, Inc.
- Inventiva Pharma
- Pharmaxis Limited
Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey
By Treatment Type:
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
By Condition:
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
